8. A randomised double-blind, double-dummy parallel group study to compare the efficacy and safety of fluticasone propionate / formoterol fumarate (flutiform®) 500/20 µg BID and 250/10 µg BID versus salmeterol / fluticasone (Seretide®) 50/500 µg BID in subjects with chronic obstructive pulmonary disease (COPD). Protocol Number: FLT3510; Mundipharma, 2015 –
9. A Multicentre, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA) Protocol Number: D3250C00021; AstraZeneca, 2015 –
10. A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of switching from salmeterol/fluticasone to QVA149 (indacaterol maleate/glycopyrronium bromide) in symptomatic COPD patients. Protocol: CQVA149A3405; Novartis, 2015 –
11. A randomised, controlled, blinded phase 1 study to evaluate the immunogenicity and safety of a pandemic avian H5 influenza vaccine in adults (FLU003). 2015
12. A randomised, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo, administered for 14 days after the onset of symptoms of an upper respiratory tract infection for the prevention of severe exacerbations (INEXAS study). Protocol Number: D6230C00001; AstraZeneca, 2015 –
13. A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in asthma patients not adequately controlled by medium- or high-dose ICS plus LABA with or without OCS. Clinical Trial Protocol: CQGE031B2204; Novartis, 2015 –
14. A 52-week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosoniphils. Protocol Number: C38072-AS-30027; Teva Branded Pharmaceutical Products R&D, Inc., 2015 -
Please e-mail the inquiries to info@arasmi.org